Mimedx Group Inc (MDXG) 7.93 $MDXG
MiMedx Reaches Settlement With Medline Industries And Liventa Bioscience For Certain Claims
PR Newswire - Tue Jun 21, 11:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the Company has agreed to terms of settlement with each of Medline Industries, Inc. ("Medline"
and Liventa Bioscience, Inc. ("Liventa" for false advertising claims asserted against each of them by MiMedx.
MDXG: 7.93 (+0.34)
Independent Clinical Case Series Demonstrates MiMedx dHACM, Along With Split Thickness Skin Grafts, Is Effective In Limb Salvage
PR Newswire - Wed Jun 01, 4:43PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the most recent peer-reviewed independent clinical case series of MiMedx EpiFix® allografts has been published. The paper, "Bone and Tendon Coverage via Dehydrated Human Amniotic/Chorionic Membrane and Split-Thickness Skin Grafting," was electronically published in the Journal of Reconstructive Microsurgery.
MDXG: 7.93 (+0.34)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Osiris Therapeutics, Inc. -- OSIR
BusinessWire - Wed Jun 01, 10:08AM CDT
Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. ("Osiris Therapeutics" or the "Company" (NASDAQ: OSIR) concerning possible violations of federal securities laws.
OSIR: 5.50 (+0.30), MDXG: 7.93 (+0.34)
MiMedx To Present At The Jefferies 2016 Global Healthcare Conference
PR Newswire - Thu May 26, 1:00PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the Jefferies 2016 Global Healthcare Conference in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP and Chief Commercialization Officer, are scheduled to present on Wednesday, June 8th at 4:30 p.m. eastern time, at the Grand Hyatt New York. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 7.93 (+0.34)
MiMedx to Attend the 13th Annual Craig-Hallum Institutional Investor Conference
PR Newswire - Mon May 23, 8:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will attend the 13th Annual Craig-Hallum Institutional Investor Conference in Minneapolis, Minnesota. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to participate in one-on-one and small group meetings on Wednesday, June 1, 2016, at The Depot Renaissance Minneapolis Hotel.
MDXG: 7.93 (+0.34)
MiMedx Provides Reminder of May 18th Annual Shareholders Meeting
PR Newswire - Tue May 17, 12:15PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, provided a reminder for the Company's Annual Shareholder meeting tomorrow, May 18, 2016, as well as a reminder that the annual meeting will be at the newer MiMedx facility located at 1828 West Oak Parkway, Marietta, Georgia. This facility is in the same business park as the MiMedx corporate headquarters and is located near the middle of the business park approximately one-half mile from the Company's main office.
MDXG: 7.93 (+0.34)
MiMedx Files Lawsuit Against Osiris For False And Misleading Representations
PR Newswire - Tue May 17, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it has filed a lawsuit under the Lanham Act against Osiris Therapeutics, Inc. for permanent injunctive relief and damages.
OSIR: 5.50 (+0.30), MDXG: 7.93 (+0.34)
MiMedx to Present at the UBS 2016 Global Healthcare Conference
PR Newswire - Mon May 16, 8:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the UBS 2016 Global Healthcare Conference in New York, NY. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP and Chief Commercialization Officer, are scheduled to present on Tuesday, May 24, 2016 at 10:30 a.m. eastern time, at the Grand Hyatt New York. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 7.93 (+0.34)
MiMedx Comments on Flawed Osiris Data Review
PR Newswire - Tue May 03, 8:04AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, responded today to highlight the substantive deficiencies and serious flaws in a recent data review reported by Osiris Therapeutics, Inc.
MDXG: 7.93 (+0.34)
MiMedx To Present At The 41st Annual Deutsche Bank Securities Healthcare Conference
PR Newswire - Thu Apr 28, 10:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will participate in the 41st Annual Deutsche Bank Securities Healthcare Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to participate on Thursday, May 5, 2016 at 10:00 a.m. eastern time, at the InterContinental Hotel. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
DB: 17.84 (+0.97), MDXG: 7.93 (+0.34)
MiMedx Announces First Quarter 2016 Results
PR Newswire - Mon Apr 25, 7:13PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its results for the first quarter of 2016.
MDXG: 7.93 (+0.34)
MiMedx Announces Release Date for 2016 First Quarter Results
PR Newswire - Tue Apr 19, 8:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that its results for the first quarter ended March 31, 2016, will be released before the opening of the market on Tuesday, April 26, 2016. MiMedx will host a live broadcast of its first quarter conference call on Tuesday, April 26, 2016, at 10:30 a.m. Eastern Time. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website, www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 7.93 (+0.34)
The Impact of MiMedx EpiFix® to be Presented at SAWC Conference
PR Newswire - Tue Apr 12, 12:34PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that nine poster abstracts showing the clinical and cost effective healing results of the Company's Dehydrated Human Amnion/Chorion Membrane (dHACM) allografts will be presented at the 2016 Symposium on Advanced Wound Care and Wound Healing Society (2016 SAWC Spring/WHS) meeting. The symposium is the leading national wound healing conference and is now in its 29th year. The 2016 SAWC Spring/WHS begins April 13, 2016, and concludes on April 17, 2016, and MiMedx will be exhibiting from April 14th through April 16th in booth #615.
MDXG: 7.93 (+0.34)
What Has MiMedx Group Shares Dropping 10% Today?
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 11, 12:57PM CDT
IMAGE SOURCE: MIMEDX GROUP, INC. What: Following news that first-quarter revenue will be shy of forecasts, shares in MiMedx Group are tumbling 10% at 1:30 p.m. ET today. So what: MiMedx develops wound-healing technologies from human...
MDXG: 7.93 (+0.34)
MiMedx Announces First Quarter of 2016 Revenue Results
PR Newswire - Sun Apr 10, 4:00PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its revenue results for the first quarter of 2016.
MDXG: 7.93 (+0.34)
5 Stocks with Surging Estimates in Q1 Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:03AM CDT
S&P 500 companies are likely to witness a 10.3% year-over-year decline in earnings in the quarter. The 5 mentioned stocks are expected to post earnings growth despite the oddities.
SFE: 12.92 (+0.42), CPN: 14.18 (+0.39), EPZM: 10.44 (-0.28), MDXG: 7.93 (+0.34), AUY: 4.85 (-0.08)
MiMedx To Present At The 15th Annual Needham Healthcare Conference
PR Newswire - Tue Apr 05, 10:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the Needham Healthcare Conference in New York, NY. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP and Chief Commercialization Officer are scheduled to present on Tuesday, April 12, 2016, 8:00 a.m. EDT, at the Westin New York Grand Central. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 7.93 (+0.34)
Why MiMedx Group (MDXG) Could Be an Impressive Growth Stock
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 7:40AM CDT
MiMedx Group (MDXG) has a favorable Zacks Rank and is a fast-growing stock that is well positioned for future earnings growth.
MDXG: 7.93 (+0.34)
4 Top Ranked Stocks to Buy Ahead of Earnings Season
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 10:08AM CDT
Get a head start on the earnings season with these top-ranked champions who are set to beat estimates.
APEI: 28.17 (+0.44), BKCC: 7.70 (+0.04), DQ: 21.10 (+0.95), MDXG: 7.93 (+0.34)
MiMedx Reaches Settlement With Medline Industries And Liventa Bioscience For Certain Claims
PR Newswire - Tue Jun 21, 11:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the Company has agreed to terms of settlement with each of Medline Industries, Inc. ("Medline"
and Liventa Bioscience, Inc. ("Liventa" for false advertising claims asserted against each of them by MiMedx. MDXG: 7.93 (+0.34)
Independent Clinical Case Series Demonstrates MiMedx dHACM, Along With Split Thickness Skin Grafts, Is Effective In Limb Salvage
PR Newswire - Wed Jun 01, 4:43PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the most recent peer-reviewed independent clinical case series of MiMedx EpiFix® allografts has been published. The paper, "Bone and Tendon Coverage via Dehydrated Human Amniotic/Chorionic Membrane and Split-Thickness Skin Grafting," was electronically published in the Journal of Reconstructive Microsurgery.
MDXG: 7.93 (+0.34)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Osiris Therapeutics, Inc. -- OSIR
BusinessWire - Wed Jun 01, 10:08AM CDT
Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. ("Osiris Therapeutics" or the "Company"
(NASDAQ: OSIR) concerning possible violations of federal securities laws. OSIR: 5.50 (+0.30), MDXG: 7.93 (+0.34)
MiMedx To Present At The Jefferies 2016 Global Healthcare Conference
PR Newswire - Thu May 26, 1:00PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the Jefferies 2016 Global Healthcare Conference in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP and Chief Commercialization Officer, are scheduled to present on Wednesday, June 8th at 4:30 p.m. eastern time, at the Grand Hyatt New York. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 7.93 (+0.34)
MiMedx to Attend the 13th Annual Craig-Hallum Institutional Investor Conference
PR Newswire - Mon May 23, 8:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will attend the 13th Annual Craig-Hallum Institutional Investor Conference in Minneapolis, Minnesota. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to participate in one-on-one and small group meetings on Wednesday, June 1, 2016, at The Depot Renaissance Minneapolis Hotel.
MDXG: 7.93 (+0.34)
MiMedx Provides Reminder of May 18th Annual Shareholders Meeting
PR Newswire - Tue May 17, 12:15PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, provided a reminder for the Company's Annual Shareholder meeting tomorrow, May 18, 2016, as well as a reminder that the annual meeting will be at the newer MiMedx facility located at 1828 West Oak Parkway, Marietta, Georgia. This facility is in the same business park as the MiMedx corporate headquarters and is located near the middle of the business park approximately one-half mile from the Company's main office.
MDXG: 7.93 (+0.34)
MiMedx Files Lawsuit Against Osiris For False And Misleading Representations
PR Newswire - Tue May 17, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it has filed a lawsuit under the Lanham Act against Osiris Therapeutics, Inc. for permanent injunctive relief and damages.
OSIR: 5.50 (+0.30), MDXG: 7.93 (+0.34)
MiMedx to Present at the UBS 2016 Global Healthcare Conference
PR Newswire - Mon May 16, 8:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the UBS 2016 Global Healthcare Conference in New York, NY. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP and Chief Commercialization Officer, are scheduled to present on Tuesday, May 24, 2016 at 10:30 a.m. eastern time, at the Grand Hyatt New York. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 7.93 (+0.34)
MiMedx Comments on Flawed Osiris Data Review
PR Newswire - Tue May 03, 8:04AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, responded today to highlight the substantive deficiencies and serious flaws in a recent data review reported by Osiris Therapeutics, Inc.
MDXG: 7.93 (+0.34)
MiMedx To Present At The 41st Annual Deutsche Bank Securities Healthcare Conference
PR Newswire - Thu Apr 28, 10:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will participate in the 41st Annual Deutsche Bank Securities Healthcare Conference in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to participate on Thursday, May 5, 2016 at 10:00 a.m. eastern time, at the InterContinental Hotel. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
DB: 17.84 (+0.97), MDXG: 7.93 (+0.34)
MiMedx Announces First Quarter 2016 Results
PR Newswire - Mon Apr 25, 7:13PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its results for the first quarter of 2016.
MDXG: 7.93 (+0.34)
MiMedx Announces Release Date for 2016 First Quarter Results
PR Newswire - Tue Apr 19, 8:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that its results for the first quarter ended March 31, 2016, will be released before the opening of the market on Tuesday, April 26, 2016. MiMedx will host a live broadcast of its first quarter conference call on Tuesday, April 26, 2016, at 10:30 a.m. Eastern Time. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website, www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MDXG: 7.93 (+0.34)
The Impact of MiMedx EpiFix® to be Presented at SAWC Conference
PR Newswire - Tue Apr 12, 12:34PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that nine poster abstracts showing the clinical and cost effective healing results of the Company's Dehydrated Human Amnion/Chorion Membrane (dHACM) allografts will be presented at the 2016 Symposium on Advanced Wound Care and Wound Healing Society (2016 SAWC Spring/WHS) meeting. The symposium is the leading national wound healing conference and is now in its 29th year. The 2016 SAWC Spring/WHS begins April 13, 2016, and concludes on April 17, 2016, and MiMedx will be exhibiting from April 14th through April 16th in booth #615.
MDXG: 7.93 (+0.34)
What Has MiMedx Group Shares Dropping 10% Today?
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 11, 12:57PM CDT
IMAGE SOURCE: MIMEDX GROUP, INC. What: Following news that first-quarter revenue will be shy of forecasts, shares in MiMedx Group are tumbling 10% at 1:30 p.m. ET today. So what: MiMedx develops wound-healing technologies from human...
MDXG: 7.93 (+0.34)
MiMedx Announces First Quarter of 2016 Revenue Results
PR Newswire - Sun Apr 10, 4:00PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today its revenue results for the first quarter of 2016.
MDXG: 7.93 (+0.34)
5 Stocks with Surging Estimates in Q1 Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:03AM CDT
S&P 500 companies are likely to witness a 10.3% year-over-year decline in earnings in the quarter. The 5 mentioned stocks are expected to post earnings growth despite the oddities.
SFE: 12.92 (+0.42), CPN: 14.18 (+0.39), EPZM: 10.44 (-0.28), MDXG: 7.93 (+0.34), AUY: 4.85 (-0.08)
MiMedx To Present At The 15th Annual Needham Healthcare Conference
PR Newswire - Tue Apr 05, 10:00AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic membrane and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at the Needham Healthcare Conference in New York, NY. Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, and Christopher M. Cashman, EVP and Chief Commercialization Officer are scheduled to present on Tuesday, April 12, 2016, 8:00 a.m. EDT, at the Westin New York Grand Central. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 7.93 (+0.34)
Why MiMedx Group (MDXG) Could Be an Impressive Growth Stock
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 7:40AM CDT
MiMedx Group (MDXG) has a favorable Zacks Rank and is a fast-growing stock that is well positioned for future earnings growth.
MDXG: 7.93 (+0.34)
4 Top Ranked Stocks to Buy Ahead of Earnings Season
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 10:08AM CDT
Get a head start on the earnings season with these top-ranked champions who are set to beat estimates.
APEI: 28.17 (+0.44), BKCC: 7.70 (+0.04), DQ: 21.10 (+0.95), MDXG: 7.93 (+0.34)
